PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Stefano Berrè

GSK, Rixensart, Belgium.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 26, 2026 · JOURNAL ARTICLE

Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.

Human Vaccines & Immunotherapeutics

Phase 2 randomized active-controlled trial in 425 vaccinated adults showing dose-dependent immunogenicity and acceptable safety profile for investigational mRNA vaccines comparable to licensed comparator, but requiring Phase 3 confirmation before clinical adoption.

PromisingStefano Berrè Antibodies, Neutralizing Martin Robert Gaudinski

Reported

Sample size425

Per-protocol immunogenicity analy…381

Randomization ratio1:1:1:1:1

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support